VivoSeq
Other

PET

0

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

PET is an early-stage landscape with 0 programs across 5 companies. The most active players are Orion Corporation, Orion Pharma, Roche, GSK.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

79/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalE

Engrail Therapeutics INC

0 programs

PreclinicalA

Avid Radiopharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

37

clinical trials

Completed22 · 59%
Unknown status7 · 19%
Terminated3 · 8%
Withdrawn3 · 8%
Recruiting2 · 5%

Clinical Trials

Trial Activity

37 trials

Test-retest Evaluation of [18F]F-AraG PET
Recruiting·CCellSight Technologies, Inc.·Phase 2·NCT06084806·10 enrolled
Glucose Consumption in MS Using [F-18]FDG-PET
Recruiting·—·Phase 4·NCT07087106·50 enrolled
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
Completed·SStanford University·Phase 1·NCT01383135·27 enrolled
A PET Study With ORM-12741
Completed·Orion Corporation, Orion Pharma logoOrion Corporation, Orion Pharma·Phase 1·NCT00829907·26 enrolled
A PET Study in Healthy Volunteers
Completed·GSK logoGSK·Phase 1·NCT01424449·7 enrolled
A PET Study With RO5545965 in Healthy Male Volunteers
Completed·Roche logoRoche·Phase 1·NCT01923025·9 enrolled
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
Completed·IIntegraGen SA·Phase 3·NCT03362684·1,808 enrolled
[11C]Yohimbine PET Study of alpha2-AR
Completed·HHospices Civils de Lyon·Phase 1·NCT03520543·16 enrolled
11C-PIB PET Study in MESA at Columbia University
Completed·—·N/A·NCT03981380·59 enrolled
PET Study With [89Zr]-Df-CriPec® Docetaxel
Completed·AAmsterdam UMC, location VUmc·Phase 1·NCT03712423·7 enrolled
Glycaemic, Insulinaemic and Appetite Responses to Two Different Types of Porridge
Completed·NNorthumbria University·N/A·NCT01222845·13 enrolled
I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
Completed·IImperial College London·Phase 1·NCT02323217·20 enrolled
Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444
Completed·IInvicro·Phase 1·NCT05009199·3 enrolled
Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline
Completed·UUniversity of Turku·Phase 1·NCT01435213·10 enrolled
Suitability of 11C-ORM-13070 as a PET Tracer
Completed·Orion Corporation, Orion Pharma logoOrion Corporation, Orion Pharma·Phase 1·NCT00735774·18 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)